COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

Detalles Bibliográficos
Autores principales: Rodriguez, Zahidee, Shane, Andi L., Verkerke, Hans, Lough, Christopher, Zimmerman, Matthew G., Suthar, Mehul, Wrammert, Jens, MacDonald, Heather, Wolf, Michael, Clarke, Shanelle, Roback, John D., Arthur, Connie M., Stowell, Sean R., Josephson, Cassandra D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
Exceptional Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509858/
https://www.ncbi.nlm.nih.gov/pubmed/32915971
http://dx.doi.org/10.1182/bloodadvances.2020002507
Descripción
Sumario:COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

Ejemplares similares